메뉴 건너뛰기




Volumn 13, Issue 4, 2011, Pages 331-349

Systematic therapy for unresectable or metastatic soft-tissue sarcomas: Past, present, and future

Author keywords

Chemotherapy; Metastatic soft tissue sarcoma; Sarcoma; Systemic therapy; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; MITOXANTRONE; MONOCLONAL ANTIBODY R1507; NAVELBINE; PACLITAXEL; PALIFOSFAMIDE; PAZOPANIB; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; REXIN G; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TH 302; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

EID: 80051665370     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0182-z     Document Type: Review
Times cited : (10)

References (129)
  • 1
    • 77955635233 scopus 로고    scopus 로고
    • Cancer statistics, 2010
    • 20610543
    • A Jemal, et al. 2010 Cancer statistics, 2010 CA Cancer J Clin. 60 5 277 300 20610543
    • (2010) CA Cancer J Clin. , vol.60 , Issue.5 , pp. 277-300
    • Jemal, A.1
  • 2
    • 40549134987 scopus 로고    scopus 로고
    • Diagnosis and management of pleomorphic sarcomas (so-called "MFH") in adults
    • DOI 10.1002/jso.20972
    • AF Nascimento CP Raut 2008 Diagnosis and management of pleomorphic sarcomas (so-called "MFH") in adults J Surg Oncol. 97 4 330 339 18286476 (Pubitemid 351358581)
    • (2008) Journal of Surgical Oncology , vol.97 , Issue.4 , pp. 330-339
    • Nascimento, A.F.1    Raut, C.P.2
  • 3
    • 0043132269 scopus 로고    scopus 로고
    • Localized extremity soft tissue sarcoma: Improved knowledge with unchanged survival over time
    • DOI 10.1200/JCO.2003.02.026
    • J Weitz CR Antonescu MF Brennan 2003 Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time J Clin Oncol. 21 14 2719 2725 12860950 (Pubitemid 46606317)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.14 , pp. 2719-2725
    • Weitz, J.1    Antonescu, C.R.2    Brennan, M.F.3
  • 4
    • 34249723214 scopus 로고    scopus 로고
    • Opportunities for improving the therapeutic ratio for patients with sarcoma
    • DOI 10.1016/S1470-2045(07)70169-9, PII S1470204507701699
    • JS Wunder, et al. 2007 Opportunities for improving the therapeutic ratio for patients with sarcoma Lancet Oncol. 8 6 513 524 17540303 (Pubitemid 46823060)
    • (2007) Lancet Oncology , vol.8 , Issue.6 , pp. 513-524
    • Wunder, J.S.1    Nielsen, T.O.2    Maki, R.G.3    O'Sullivan, B.4    Alman, B.A.5
  • 5
    • 41149169284 scopus 로고    scopus 로고
    • Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients
    • DOI 10.1002/cncr.23332
    • V Karavasilis, et al. 2008 Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients Cancer. 112 7 1585 1591 18278813 (Pubitemid 351441172)
    • (2008) Cancer , vol.112 , Issue.7 , pp. 1585-1591
    • Karavasilis, V.1    Seddon, B.M.2    Ashley, S.3    Al-Muderis, O.4    Fisher, C.5    Judson, I.6
  • 6
    • 0032952928 scopus 로고    scopus 로고
    • Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline- containing first-line regimens - A European organization for research and treatment of cancer soft tissue and bone sarcoma group study
    • M Van Glabbeke, et al. 1999 Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol. 17 1 150 157 10458228 A large meta-analysis to determine the efficacy of anthracycline regimens in treatment of sarcoma in the first-line setting (Pubitemid 29022388)
    • (1999) Journal of Clinical Oncology , vol.17 , Issue.1 , pp. 150-157
    • Van Glabbeke, M.1    Van Oosterom, A.T.2    Oosterhuis, J.W.3    Mouridsen, H.4    Crowther, D.5    Somers, R.6    Verweij, J.7    Santoro, A.8    Buesa, J.9    Tursz, T.10
  • 7
    • 59449090129 scopus 로고    scopus 로고
    • MFH revisited: Outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities-an analysis of 140 patients
    • 18584203
    • M Lehnhardt, et al. 2009 MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities-an analysis of 140 patients Langenbecks Arch Surg. 394 2 313 320 18584203
    • (2009) Langenbecks Arch Surg. , vol.394 , Issue.2 , pp. 313-320
    • Lehnhardt, M.1
  • 8
    • 34848882533 scopus 로고    scopus 로고
    • Soft tissue sarcomas: The role of histology and molecular pathology for differential diagnosis
    • 17867581 1:CAS:528:DC%2BD2sXitVaru7c%3D
    • C Poremba 2006 Soft tissue sarcomas: the role of histology and molecular pathology for differential diagnosis Verh Dtsch Ges Pathol. 90 59 72 17867581 1:CAS:528:DC%2BD2sXitVaru7c%3D
    • (2006) Verh Dtsch Ges Pathol. , vol.90 , pp. 59-72
    • Poremba, C.1
  • 9
    • 68249145205 scopus 로고    scopus 로고
    • Pathology of soft-tissue tumors: Daily diagnosis, molecular cytogenetics and experimental approach
    • 19627534 1:CAS:528:DC%2BD1MXhtFWjtLzF
    • H Iwasaki, et al. 2009 Pathology of soft-tissue tumors: daily diagnosis, molecular cytogenetics and experimental approach Pathol Int. 59 8 501 521 19627534 1:CAS:528:DC%2BD1MXhtFWjtLzF
    • (2009) Pathol Int. , vol.59 , Issue.8 , pp. 501-521
    • Iwasaki, H.1
  • 10
    • 0023176119 scopus 로고
    • Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas
    • EC Borden, et al. 1987 Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas J Clin Oncol. 5 6 840 850 3585441 1:STN:280:DyaL2s3isFWjtA%3D%3D (Pubitemid 17119988)
    • (1987) Journal of Clinical Oncology , vol.5 , Issue.6 , pp. 840-850
    • Borden, E.C.1    Amato, D.A.2    Rosenbaum, C.3
  • 11
    • 80051666640 scopus 로고    scopus 로고
    • Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma
    • EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study
    • Gelderblom H, et al. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. ASCO Meeting Abstracts. 2010;28(15 suppl):10037.
    • (2010) ASCO Meeting Abstracts , vol.28 , Issue.15 SUPPL. , pp. 10037
    • Gelderblom, H.1
  • 13
    • 34547688913 scopus 로고    scopus 로고
    • Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study
    • DOI 10.1200/JCO.2006.09.7717
    • P Lorigan, et al. 2007 Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol. 25 21 3144 3150 17634494 1:CAS:528:DC%2BD2sXptlGrt7k%3D (Pubitemid 47218064)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.21 , pp. 3144-3150
    • Lorigan, P.1    Verweij, J.2    Papai, Z.3    Rodenhuis, S.4    Le Cesne, A.5    Leahy, M.G.6    Radford, J.A.7    Van Glabbeke, M.M.8    Kirkpatrick, A.9    Hogendoorn, P.C.W.10    Blay, J.-Y.11
  • 14
    • 64749115863 scopus 로고    scopus 로고
    • Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish group for research on sarcomas
    • 19273704 1:CAS:528:DC%2BD1MXltlSisbY%3D
    • J Maurel, et al. 2009 Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas J Clin Oncol. 27 11 1893 1898 19273704 1:CAS:528:DC%2BD1MXltlSisbY%3D
    • (2009) J Clin Oncol. , vol.27 , Issue.11 , pp. 1893-1898
    • Maurel, J.1
  • 15
    • 0023428586 scopus 로고
    • Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group
    • 3479329 1:STN:280:DyaL1c%2FlsFajtw%3D%3D
    • HT Mouridsen, et al. 1987 Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer Clin Oncol. 23 10 1477 1483 3479329 1:STN:280:DyaL1c%2FlsFajtw%3D%3D
    • (1987) Eur J Cancer Clin Oncol. , vol.23 , Issue.10 , pp. 1477-1483
    • Mouridsen, H.T.1
  • 17
    • 0029005580 scopus 로고
    • Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    • 7602342 1:STN:280:DyaK2MzisFylug%3D%3D
    • A Santoro, et al. 1995 Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J Clin Oncol. 13 7 1537 1545 7602342 1:STN:280:DyaK2MzisFylug%3D%3D A large randomized phase 3 study demonstrating no statistically significant difference in ORR or OS between doxorubicin alone compared to doxorubicin plus ifosfamide
    • (1995) J Clin Oncol. , vol.13 , Issue.7 , pp. 1537-1545
    • Santoro, A.1
  • 18
    • 18144448739 scopus 로고    scopus 로고
    • Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    • J Verweij, et al. 2000 Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group J Clin Oncol. 18 10 2081 2086 10811673 1:CAS:528:DC%2BD3cXktVyjsLY%3D (Pubitemid 30324361)
    • (2000) Journal of Clinical Oncology , vol.18 , Issue.10 , pp. 2081-2086
    • Verweij, J.1    Lee, S.M.2    Ruka, W.3    Buesa, J.4    Coleman, R.5    Van Hoessel, R.6    Seynaeve, C.7    Di Paola, E.D.8    Van Glabbeke, M.9    Tonelli, D.10    Judson, I.R.11
  • 19
    • 0027256397 scopus 로고
    • Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas
    • JH Edmonson, et al. 1993 Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas J Clin Oncol. 11 7 1269 1275 8315424 1:STN:280:DyaK3szgtFKlsg%3D%3D A randomized phase 3 study demonstrating that ifosfamide plus doxorubicin yields a statistically significant increase in ORR compared to doxorubicin alone, but both regimens lead to similar overall survival outcomes (Pubitemid 23199129)
    • (1993) Journal of Clinical Oncology , vol.11 , Issue.7 , pp. 1269-1275
    • Edmonson, J.H.1    Ryan, L.M.2    Blum, R.H.3    Brooks, J.S.J.4    Shiraki, M.5    Frytak, S.6    Parkinson, D.R.7
  • 20
    • 71049122368 scopus 로고    scopus 로고
    • Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
    • 19853437 1:CAS:528:DC%2BD1MXhsFGrsbvF
    • S Sleijfer, et al. 2010 Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) Eur J Cancer. 46 1 72 83 19853437 1:CAS:528:DC%2BD1MXhsFGrsbvF An important meta-analysis that establishes the prognostic and predictive factors for outcome of ifosfamide-containing regimens compared to doxorubicin-containing therapy in the first-line setting. Also important for benchmarks of single-agent doxorubicin
    • (2010) Eur J Cancer. , vol.46 , Issue.1 , pp. 72-83
    • Sleijfer, S.1
  • 21
    • 80051663984 scopus 로고    scopus 로고
    • Adriamycin, [package insert]. USA: Pharmacia & Upjohn, 1997
    • Adriamycin, [package insert]. USA: Pharmacia & Upjohn, 1997.
  • 22
    • 77953931502 scopus 로고    scopus 로고
    • Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
    • 20587042
    • LA Smith, et al. 2010 Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials BMC Cancer. 10 337 20587042 A systematic review and meta-analysis to identify the risk of cardiotoxicity of anthracycline agents
    • (2010) BMC Cancer. , vol.10 , pp. 337
    • Smith, L.A.1
  • 23
    • 0026042237 scopus 로고
    • A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors
    • 1873773 1:STN:280:DyaK3MzjvFSqtA%3D%3D
    • ES Casper, et al. 1991 A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors Cancer. 68 6 1221 1229 1873773 1:STN:280:DyaK3MzjvFSqtA%3D%3D
    • (1991) Cancer. , vol.68 , Issue.6 , pp. 1221-1229
    • Casper, E.S.1
  • 24
    • 0025770430 scopus 로고
    • Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study
    • 2067035 1:STN:280:DyaK3M3psFagsA%3D%3D
    • M Zalupski, et al. 1991 Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study J Natl Cancer Inst. 83 13 926 932 2067035 1:STN:280:DyaK3M3psFagsA%3D%3D
    • (1991) J Natl Cancer Inst. , vol.83 , Issue.13 , pp. 926-932
    • Zalupski, M.1
  • 25
    • 0033929703 scopus 로고    scopus 로고
    • Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The experience of the EORTC soft tissue and bone sarcoma group
    • OS Nielsen, et al. 2000 Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue Sarcomas. The Experience of the EORTC Soft Tissue and Bone Sarcoma Group Sarcoma. 4 1-2 31 35 18521432 1:CAS:528: DC%2BD3cXlslCqu7s%3D (Pubitemid 30480279)
    • (2000) Sarcoma , vol.4 , Issue.1-2 , pp. 31-35
    • Nielsen, O.S.1    Dombernowsky, P.2    Mouridsen, H.3    Daugaard, S.4    Van Glabbeke, M.5    Kirkpatrick, A.6    Verweij, J.7
  • 26
    • 0021997261 scopus 로고
    • Phase II trial of mitoxantrone in advanced sarcomas: A Southwest Oncology Group study
    • FE Bull, et al. 1985 Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study Cancer Treat Rep. 69 2 231 233 3882233 1:STN:280:DyaL2M7isVCrtQ%3D%3D (Pubitemid 15170466)
    • (1985) Cancer Treatment Reports , vol.69 , Issue.2 , pp. 231-233
    • Bull, F.E.1    Von Hoff, D.D.2    Balcerzak, S.P.3
  • 27
    • 0023442506 scopus 로고
    • Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas
    • 3119206 1:STN:280:DyaL1c%2Flt1Oitw%3D%3D
    • I Quirt, et al. 1987 Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas Cancer Treat Rep. 71 11 1109 1110 3119206 1:STN:280:DyaL1c%2Flt1Oitw%3D%3D
    • (1987) Cancer Treat Rep. , vol.71 , Issue.11 , pp. 1109-1110
    • Quirt, I.1
  • 28
    • 77957241407 scopus 로고    scopus 로고
    • Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion
    • 20795769 1:CAS:528:DC%2BC3cXht1SnsbbF
    • WW Huh, et al. 2010 Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion Pediatr Hematol Oncol. 27 7 546 557 20795769 1:CAS:528:DC%2BC3cXht1SnsbbF
    • (2010) Pediatr Hematol Oncol. , vol.27 , Issue.7 , pp. 546-557
    • Huh, W.W.1
  • 31
    • 0037740979 scopus 로고    scopus 로고
    • Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in sarcoma
    • DOI 10.1081/CNV-120016412
    • KM Skubitz 2003 Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma Cancer Investig. 21 2 167 176 1:CAS:528:DC%2BD3sXktVOmu70%3D (Pubitemid 36532162)
    • (2003) Cancer Investigation , vol.21 , Issue.2 , pp. 167-176
    • Skubitz, K.M.1
  • 32
    • 0034109686 scopus 로고    scopus 로고
    • Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: A phase II study of the Italian Sarcoma Group (ISG)
    • S Toma, et al. 2000 Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG) Anticancer Res. 20 1B 485 491 10769710 1:CAS:528:DC%2BD3cXisl2gurc%3D (Pubitemid 30189706)
    • (2000) Anticancer Research , vol.20 , Issue.1 B , pp. 485-491
    • Toma, S.1    Tucci, A.2    Villani, G.3    Carteni, G.4    Spadini, N.5    Palumbo, R.6
  • 33
    • 0030994523 scopus 로고    scopus 로고
    • Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma
    • ES Casper, et al. 1997 Phase I trial of dose-intense liposome- encapsulated doxorubicin in patients with advanced sarcoma J Clin Oncol. 15 5 2111 2117 9164225 1:CAS:528:DyaK2sXjsVCrtbw%3D (Pubitemid 27209544)
    • (1997) Journal of Clinical Oncology , vol.15 , Issue.5 , pp. 2111-2117
    • Casper, E.S.1    Schwartz, G.K.2    Sugarman, A.3    Leung, D.4    Brennan, M.F.5
  • 34
    • 33746601850 scopus 로고    scopus 로고
    • A Phase II nonrandomised open-label study of liposomal Daunorubicin (DaunoXome) in advanced soft tissue Sarcoma
    • 17040090
    • A McTiernan, et al. 2006 A Phase II nonrandomised open-label study of liposomal Daunorubicin (DaunoXome) in advanced soft tissue Sarcoma Sarcoma. 2006 1 41080 17040090
    • (2006) Sarcoma. , vol.2006 , Issue.1 , pp. 41080
    • McTiernan, A.1
  • 35
    • 27244450145 scopus 로고    scopus 로고
    • Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas
    • 16192597
    • DR D'Adamo, et al. 2005 Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas J Clin Oncol. 23 28 7135 7142 16192597
    • (2005) J Clin Oncol. , vol.23 , Issue.28 , pp. 7135-7142
    • D'Adamo, D.R.1
  • 36
    • 36849015252 scopus 로고    scopus 로고
    • The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas
    • DOI 10.1634/theoncologist.12-11-1351
    • M Tascilar, et al. 2007 The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas Oncologist. 12 11 1351 1360 18055856 1:CAS:528:DC%2BD1cXivVShtQ%3D%3D (Pubitemid 350232609)
    • (2007) Oncologist , vol.12 , Issue.11 , pp. 1351-1360
    • Tascilar, M.1    Loos, W.J.2    Seynaeve, C.3    Verweij, J.4    Sleijfer, S.5
  • 37
    • 0027533415 scopus 로고
    • Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group
    • 8453694
    • VH Bramwell, et al. 1993 Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group Cancer Chemother Pharmacol. 31 Suppl 2 S180 S184 8453694
    • (1993) Cancer Chemother Pharmacol. , vol.31 , Issue.SUPPL. 2
    • Bramwell, V.H.1
  • 41
    • 0030726408 scopus 로고    scopus 로고
    • Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas
    • DOI 10.1023/A:1008279426654
    • R Palumbo, et al. 1997 Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas Ann Oncol. 8 11 1159 1162 9426338 1:STN:280:DyaK1c%2FoslOiug%3D%3D (Pubitemid 27521226)
    • (1997) Annals of Oncology , vol.8 , Issue.11 , pp. 1159-1162
    • Palumbo, R.1    Palmeri, S.2    Antimi, M.3    Gatti, C.4    Raffo, P.5    Villani, G.6    Toma, S.7
  • 44
    • 0031706550 scopus 로고    scopus 로고
    • High-dose ifosfamide for soft tissue sarcomas: Set the scene, or senescence?: Editorial
    • DOI 10.1023/A:1008461922040
    • J Verweij 1998 High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence? Ann Oncol. 9 8 807 809 9789601 1:STN:280: DyaK1M%2Fgs1Sgsg%3D%3D (Pubitemid 28440437)
    • (1998) Annals of Oncology , vol.9 , Issue.8 , pp. 807-809
    • Verweij, J.1
  • 45
    • 0028284326 scopus 로고
    • Synovial sarcoma: Uniform response of metastases to high dose ifosfamide
    • DOI 10.10 02/1097-0142(199 40515)73:10<2506::AID-CN CR2820731009>3.0.CO;2-S
    • G Rosen, et al. 1994 Synovial sarcoma. Uniform response of metastases to high dose ifosfamide Cancer. 73 10 2506 2511 8174046 1:STN:280: DyaK2c3ivVCgsQ%3D%3D (Pubitemid 24155525)
    • (1994) Cancer , vol.73 , Issue.10 , pp. 2506-2511
    • Rosen, G.1    Forscher, C.2    Lowenbraun, S.3    Eilber, F.4    Eckardt, J.5    Holmes, C.6    Fu, Y.S.7
  • 46
    • 71949085741 scopus 로고    scopus 로고
    • Preliminary efficacy and safety results of glufosfamide (GLU) in relapsed soft tissue sarcoma: Results of a phase II trial
    • D'Amato GZ, et al. Preliminary efficacy and safety results of glufosfamide (GLU) in relapsed soft tissue sarcoma: results of a phase II trial. ASCO Meeting Abstracts. 2008;26(15 suppl):10591.
    • (2008) ASCO Meeting Abstracts , vol.26 , Issue.15 SUPPL. , pp. 10591
    • D'Amato, G.Z.1
  • 47
    • 77957936131 scopus 로고    scopus 로고
    • A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO)
    • Verschraegen CF, et al. A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). ASCO Meeting Abstracts. 2010;28(15 suppl):10004.
    • (2010) ASCO Meeting Abstracts , vol.28 , Issue.15 SUPPL. , pp. 10004
    • Verschraegen, C.F.1
  • 49
    • 0033941746 scopus 로고    scopus 로고
    • Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus infosfamide plus recombinant human granulocyte-macrophage colony- stimulating factor in advanced soft tissue sarcomas: A trial of the european organization for research and treatment of cancer/soft tissue and bone sarcoma group
    • A Le Cesne, et al. 2000 Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group J Clin Oncol. 18 14 2676 2684 10894866 (Pubitemid 30463549)
    • (2000) Journal of Clinical Oncology , vol.18 , Issue.14 , pp. 2676-2684
    • Le Cesne, A.1    Judson, I.2    Crowther, D.3    Rodenhuis, S.4    Keizer, H.J.5    Van Hoesel, Q.6    Blay, J.Y.7    Frisch, J.8    Van Glabbeke, M.9    Hermans, C.10    Van Oosterom, A.11    Tursz, T.12    Verweij, J.13
  • 52
    • 22544453003 scopus 로고    scopus 로고
    • Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: Results of a phase II study
    • DOI 10.1002/cncr.21211
    • JM Siehl, et al. 2005 Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study Cancer. 104 3 611 617 15968689 1:CAS:528:DC%2BD2MXpt1els7o%3D (Pubitemid 41022820)
    • (2005) Cancer , vol.104 , Issue.3 , pp. 611-617
    • Siehl, J.M.1    Thiel, E.2    Schmittel, A.3    Hutter, G.4    Deckert, P.M.5    Szelenyi, H.6    Keilholz, U.7
  • 53
    • 16644397432 scopus 로고    scopus 로고
    • 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma
    • DOI 10.1200/JCO.2005.05.108
    • FP Worden, et al. 2005 Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma J Clin Oncol. 23 1 105 112 15625365 1:CAS:528:DC%2BD2MXpslaksQ%3D%3D (Pubitemid 41702628)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.1 , pp. 105-112
    • Worden, F.P.1    Taylor, J.M.G.2    Biermann, J.S.3    Sondak, V.K.4    Leu, K.M.5    Chugh, R.6    McGinn, C.J.7    Zalupski, M.M.8    Baker, L.H.9
  • 57
    • 55949086834 scopus 로고    scopus 로고
    • Phase II trial of weekly paclitaxel for unresectable angiosarcoma: The ANGIOTAX Study
    • 18809609 1:CAS:528:DC%2BD1cXhsVyqsrbJ
    • N Penel, et al. 2008 Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study J Clin Oncol. 26 32 5269 5274 18809609 1:CAS:528:DC%2BD1cXhsVyqsrbJ Although this is a small phase 2 study, it confirmed observations in other trials which suggested that paclitaxel single agent is active in angiosarcoma
    • (2008) J Clin Oncol. , vol.26 , Issue.32 , pp. 5269-5274
    • Penel, N.1
  • 58
    • 33745458519 scopus 로고    scopus 로고
    • Albumin-bound paclitaxel: A next-generation taxane
    • DOI 10.1517/14656566.7.8.1041
    • WJ Gradishar 2006 Albumin-bound paclitaxel: a next-generation taxane Expert Opin Pharmacother. 7 8 1041 1053 16722814 1:CAS:528:DC%2BD28XltVOgsrg%3D (Pubitemid 43949942)
    • (2006) Expert Opinion on Pharmacotherapy , vol.7 , Issue.8 , pp. 1041-1053
    • Gradishar, W.J.1
  • 59
    • 80051669940 scopus 로고    scopus 로고
    • A phase II study of nanoparticle albumin-bound (nab) paclitaxel in the treatment of patients with unresectable or metastatic sarcoma
    • • Butrynski JE, et al. A phase II study of nanoparticle albumin-bound (nab) paclitaxel in the treatment of patients with unresectable or metastatic sarcoma. CTOS Meeting Abstracts, 2010(Abstract #901186). Despite the negative data in this study for nab-paclitaxel as a single agent, this agent may hold potential if used as part of a combination regimen.
    • CTOS Meeting Abstracts, 2010(Abstract #901186)
    • Butrynski, J.E.1
  • 62
    • 53149109402 scopus 로고    scopus 로고
    • Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: A mono-institutional phase II study
    • 18351342 1:CAS:528:DC%2BD1cXhtF2kur%2FO
    • V Ferraresi, et al. 2008 Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study Cancer Chemother Pharmacol. 63 1 149 155 18351342 1:CAS:528:DC%2BD1cXhtF2kur%2FO
    • (2008) Cancer Chemother Pharmacol. , vol.63 , Issue.1 , pp. 149-155
    • Ferraresi, V.1
  • 63
    • 33646567780 scopus 로고    scopus 로고
    • An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
    • DOI 10.1007/s10637-005-3537-1
    • JT Hartmann, et al. 2006 An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma Invest New Drugs. 24 3 249 253 16133789 1:CAS:528: DC%2BD28XktlWls7s%3D (Pubitemid 43723900)
    • (2006) Investigational New Drugs , vol.24 , Issue.3 , pp. 249-253
    • Hartmann, J.T.1    Oechsle, K.2    Huober, J.3    Jakob, A.4    Azemar, M.5    Horger, M.6    Kanz, L.7    Bokemeyer, C.8
  • 69
    • 77955231655 scopus 로고    scopus 로고
    • Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study
    • • Garcia Del Muro X, et al. Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: a Spanish Group for Research on Sarcomas (GEIS) study. ASCO Meeting Abstracts. 2009;27(15S):10529. The combination of gemcitabine and dacarbazine appears very promising. It may have lower toxicity and similar efficacy to gemcitabine and docetaxel-based regimens. Awaiting publication of these results in formal manuscript.
    • (2009) ASCO Meeting Abstracts , vol.27 , Issue.15 , pp. 10529
    • Garcia Del Muro, X.1
  • 70
    • 2442635522 scopus 로고    scopus 로고
    • Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma
    • DOI 10.1200/JCO.2004.08.043
    • KM Leu, et al. 2004 Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma J Clin Oncol. 22 9 1706 1712 15117993 1:CAS:528:DC%2BD2cXpsVWls78%3D Interesting in vitro data demonstrating that the sequential treatment of gemcitabine followed by docetaxel was synergistic, whereas simultaneous treatment led to antagonistic effects. Another component of this study is a retrospective analysis to identify the efficacy of gemcitabine/docetaxel by histologic subtype (Pubitemid 41079810)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.9 , pp. 1706-1712
    • Leu, K.M.1    Ostruszka, L.J.2    Shewach, D.3    Zalupski, M.4    Sondak, V.5    Sybil Biertnann, J.6    Lee, J.S.-J.7    Couwlier, C.8    Palazzolo, K.9    Baker, L.H.10
  • 71
    • 34548461654 scopus 로고    scopus 로고
    • Gemcitabine and docetaxel in metastatic sarcoma: Past, present, and future
    • DOI 10.1634/theoncologist.12-8-999
    • RG Maki 2007 Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future Oncologist. 12 8 999 1006 17766660 1:CAS:528: DC%2BD2sXhtFWgsbnN (Pubitemid 47359143)
    • (2007) Oncologist , vol.12 , Issue.8 , pp. 999-1006
    • Maki, R.G.1
  • 73
    • 80051664659 scopus 로고    scopus 로고
    • Phase II study of weekly docetaxel and fixed-dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma
    • Abstract #897230
    • Ahn J, et al. Phase II study of weekly docetaxel and fixed-dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. CTOS Meeting Abstracts, 2010(Abstract #897230).
    • (2010) CTOS Meeting Abstracts
    • Ahn, J.1
  • 74
    • 80051665327 scopus 로고    scopus 로고
    • A phase II study of low dose TAG (taxotere, adriamycin, gemcitabine) as salvage therapy for soft tissue sarcoma
    • Abstract #896893
    • Ganjoo KN, et al. A phase II study of low dose TAG (taxotere, adriamycin, gemcitabine) as salvage therapy for soft tissue sarcoma. CTOS Meeting Abstracts, 2010(Abstract #896893).
    • (2010) CTOS Meeting Abstracts
    • Ganjoo, K.N.1
  • 75
    • 79954902015 scopus 로고    scopus 로고
    • Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma
    • Seddon BM, et al. Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma. ASCO Meeting Abstracts. 2009;27(15S):10528.
    • (2009) ASCO Meeting Abstracts , vol.27 , Issue.15 , pp. 10528
    • Seddon, B.M.1
  • 76
    • 77955505177 scopus 로고    scopus 로고
    • A review of trabectedin (ET-743): A unique mechanism of action
    • 20647340 Detailed description of the unique mechanisms of actions of this novel compound
    • M D'Incalci CM Galmarini 2010 A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther. 9 8 2157 2163 20647340 Detailed description of the unique mechanisms of actions of this novel compound
    • (2010) Mol Cancer Ther. , vol.9 , Issue.8 , pp. 2157-2163
    • D'Incalci, M.1    Galmarini, C.M.2
  • 77
    • 24944460785 scopus 로고    scopus 로고
    • Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
    • 16110008 1:CAS:528:DC%2BD2MXhtVersr%2FM
    • R Garcia-Carbonero, et al. 2005 Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clin Oncol. 23 24 5484 5492 16110008 1:CAS:528:DC%2BD2MXhtVersr%2FM
    • (2005) J Clin Oncol. , vol.23 , Issue.24 , pp. 5484-5492
    • Garcia-Carbonero, R.1
  • 78
    • 77953888624 scopus 로고    scopus 로고
    • Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program
    • Blay J, et al. Trabectedin for advanced sarcomas failing doxorubicin: analysis of 189 unreported patients in a compassionate use program. ASCO Meeting Abstracts. 2009;27(15S):10574.
    • (2009) ASCO Meeting Abstracts , vol.27 , Issue.15 , pp. 10574
    • Blay, J.1
  • 80
    • 20044372153 scopus 로고    scopus 로고
    • Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
    • 15659504
    • A Le Cesne, et al. 2005 Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial J Clin Oncol. 23 3 576 584 15659504
    • (2005) J Clin Oncol. , vol.23 , Issue.3 , pp. 576-584
    • Le Cesne, A.1
  • 81
    • 71649086663 scopus 로고    scopus 로고
    • Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute
    • Mohan V, et al. Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute. ASCO Meeting Abstracts. 2008;26(15 suppl):21506.
    • (2008) ASCO Meeting Abstracts , vol.26 , Issue.15 SUPPL. , pp. 21506
    • Mohan, V.1
  • 82
    • 80051666206 scopus 로고    scopus 로고
    • Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study
    • Samuels BL, et al. Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study. ASCO Meeting Abstracts. 2010;28(15 suppl):10027.
    • (2010) ASCO Meeting Abstracts , vol.28 , Issue.15 SUPPL. , pp. 10027
    • Samuels, B.L.1
  • 84
    • 70249101414 scopus 로고    scopus 로고
    • Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules
    • 19652065 1:CAS:528:DC%2BD1MXhtF2jtLrL
    • GD Demetri, et al. 2009 Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol. 27 25 4188 4196 19652065 1:CAS:528: DC%2BD1MXhtF2jtLrL
    • (2009) J Clin Oncol. , vol.27 , Issue.25 , pp. 4188-4196
    • Demetri, G.D.1
  • 85
    • 69249095786 scopus 로고    scopus 로고
    • Long-term benefit from trabectedin (T) in myxoid liposarcoma (MLS) patients
    • Grosso F, et al. Long-term benefit from trabectedin (T) in myxoid liposarcoma (MLS) patients. ASCO Meeting Abstracts. 2008;26(15 suppl):10582.
    • (2008) ASCO Meeting Abstracts , vol.26 , Issue.15 SUPPL. , pp. 10582
    • Grosso, F.1
  • 86
    • 76749100603 scopus 로고    scopus 로고
    • Advances in the treatment of gastrointestinal stromal tumor
    • 19802531
    • D D'Adamo 2009 Advances in the treatment of gastrointestinal stromal tumor Adv Ther. 26 9 826 837 19802531
    • (2009) Adv Ther. , vol.26 , Issue.9 , pp. 826-837
    • D'Adamo, D.1
  • 88
    • 0036305274 scopus 로고    scopus 로고
    • Clinical management of gastrointestinal stromal tumors: Before and after STI-571
    • DOI 10.1053/hupa.2002.124122
    • RP Dematteo, et al. 2002 Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol. 33 5 466 477 12094371 1:CAS:528:DC%2BD38XlslCls7o%3D (Pubitemid 34747865)
    • (2002) Human Pathology , vol.33 , Issue.5 , pp. 466-477
    • Dematteo, R.P.1    Heinrich, M.C.2    El-Rifai, W.M.3    Demetri, G.4
  • 90
    • 4644312266 scopus 로고    scopus 로고
    • Biology of gastrointestinal stromal tumors
    • DOI 10.1200/JCO.2004.05.140
    • CL Corless JA Fletcher MC Heinrich 2004 Biology of gastrointestinal stromal tumors J Clin Oncol. 22 18 3813 3825 15365079 1:CAS:528: DC%2BD2cXhtVCitb%2FL (Pubitemid 41095223)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.18 , pp. 3813-3825
    • Corless, C.L.1    Fletcher, J.A.2    Heinrich, M.C.3
  • 91
    • 80051666051 scopus 로고    scopus 로고
    • A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-{alpha} or -{beta} (PDGFR-{alpha}/PDGFR-{beta}): An Italian Sarcoma Group study
    • Grignani G, et al. A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-{alpha} or -{beta} (PDGFR-{alpha}/PDGFR-{beta}): An Italian Sarcoma Group study. ASCO Meeting Abstracts. 2010;28(15 suppl):10060.
    • (2010) ASCO Meeting Abstracts , vol.28 , Issue.15 SUPPL. , pp. 10060
    • Grignani, G.1
  • 92
    • 78149452583 scopus 로고    scopus 로고
    • Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma
    • 20953927 1:CAS:528:DC%2BC3cXht12qu7nJ
    • H Sugiura, et al. 2010 Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma J Orthop Sci. 15 5 654 660 20953927 1:CAS:528:DC%2BC3cXht12qu7nJ
    • (2010) J Orthop Sci. , vol.15 , Issue.5 , pp. 654-660
    • Sugiura, H.1
  • 93
    • 0142121411 scopus 로고    scopus 로고
    • Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
    • DOI 10.1016/S0959-8049(02)00836-5
    • J Verweij, et al. 2003 Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study Eur J Cancer. 39 14 2006 2011 12957454 1:CAS:528:DC%2BD3sXmvVKgtrc%3D (Pubitemid 37297756)
    • (2003) European Journal of Cancer , vol.39 , Issue.14 , pp. 2006-2011
    • Verweij, J.1    Van Oosterom, A.2    Blay, J.-Y.3    Judson, I.4    Rodenhuis, S.5    Van Der Graaf, W.6    Radford, J.7    Le Cesne, A.8    Hogendoorn, P.C.W.9    Di Paola, E.D.10    Brown, M.11    Nielsen, O.S.12
  • 94
    • 67650302850 scopus 로고    scopus 로고
    • Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model
    • 19451433 1:CAS:528:DC%2BD1MXhtFWitb3L
    • R Chugh, et al. 2009 Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model J Clin Oncol. 27 19 3148 3153 19451433 1:CAS:528:DC%2BD1MXhtFWitb3L
    • (2009) J Clin Oncol. , vol.27 , Issue.19 , pp. 3148-3153
    • Chugh, R.1
  • 95
    • 41549158178 scopus 로고    scopus 로고
    • Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
    • 18296418
    • JY Blay, et al. 2008 Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT) Ann Oncol. 19 4 821 822 18296418
    • (2008) Ann Oncol. , vol.19 , Issue.4 , pp. 821-822
    • Blay, J.Y.1
  • 97
    • 34247486113 scopus 로고    scopus 로고
    • A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis
    • Chugh R, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. ASCO Meeting Abstracts. 2006;24(18 suppl):9515.
    • (2006) ASCO Meeting Abstracts , vol.24 , Issue.18 SUPPL. , pp. 9515
    • Chugh, R.1
  • 98
    • 77950469922 scopus 로고    scopus 로고
    • Imatinib mesylate in advanced dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials
    • 20194851 1:CAS:528:DC%2BC3cXmtVyhu74%3D
    • P Rutkowski, et al. 2010 Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials J Clin Oncol. 28 10 1772 1779 20194851 1:CAS:528:DC%2BC3cXmtVyhu74%3D
    • (2010) J Clin Oncol. , vol.28 , Issue.10 , pp. 1772-1779
    • Rutkowski, P.1
  • 99
    • 67650312341 scopus 로고    scopus 로고
    • Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
    • 19451429 1:CAS:528:DC%2BD1MXhtFWitb3E
    • S George, et al. 2009 Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas J Clin Oncol. 27 19 3154 3160 19451429 1:CAS:528:DC%2BD1MXhtFWitb3E
    • (2009) J Clin Oncol. , vol.27 , Issue.19 , pp. 3154-3160
    • George, S.1
  • 100
    • 56149090573 scopus 로고    scopus 로고
    • Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas
    • Vigil CE, et al. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas. ASCO Meeting Abstracts. 2008;26(15 suppl):10535.
    • (2008) ASCO Meeting Abstracts , vol.26 , Issue.15 SUPPL. , pp. 10535
    • Vigil, C.E.1
  • 101
    • 56749102511 scopus 로고    scopus 로고
    • Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505
    • Ryan CW, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. ASCO Meeting Abstracts. 2008;26(15 suppl):10532.
    • (2008) ASCO Meeting Abstracts , vol.26 , Issue.15 SUPPL. , pp. 10532
    • Ryan, C.W.1
  • 102
    • 67650293850 scopus 로고    scopus 로고
    • Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    • 19451436 1:CAS:528:DC%2BD1MXhtFWitb3J
    • RG Maki, et al. 2009 Phase II study of sorafenib in patients with metastatic or recurrent sarcomas J Clin Oncol. 27 19 3133 3140 19451436 1:CAS:528:DC%2BD1MXhtFWitb3J
    • (2009) J Clin Oncol. , vol.27 , Issue.19 , pp. 3133-3140
    • Maki, R.G.1
  • 103
    • 67650337802 scopus 로고    scopus 로고
    • Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)
    • 19451427 1:CAS:528:DC%2BD1MXhtFWitb3P
    • S Sleijfer, et al. 2009 Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol. 27 19 3126 3132 19451427 1:CAS:528:DC%2BD1MXhtFWitb3P
    • (2009) J Clin Oncol. , vol.27 , Issue.19 , pp. 3126-3132
    • Sleijfer, S.1
  • 104
    • 84875158718 scopus 로고    scopus 로고
    • Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma
    • Schuetze S, et al. Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. ASCO Meeting Abstracts. 2010;28(15 suppl):10009.
    • (2010) ASCO Meeting Abstracts , vol.28 , Issue.15 SUPPL. , pp. 10009
    • Schuetze, S.1
  • 105
    • 56749170762 scopus 로고    scopus 로고
    • Angiogenesis inhibition in non-GIST soft tissue sarcomas
    • 18987047 1:CAS:528:DC%2BD1MXmtVGjug%3D%3D
    • S Sleijfer WT van der Graaf JY Blay 2008 Angiogenesis inhibition in non-GIST soft tissue sarcomas Oncologist. 13 11 1193 1200 18987047 1:CAS:528:DC%2BD1MXmtVGjug%3D%3D
    • (2008) Oncologist. , vol.13 , Issue.11 , pp. 1193-1200
    • Sleijfer, S.1    Van Der Graaf, W.T.2    Blay, J.Y.3
  • 106
    • 76649116073 scopus 로고    scopus 로고
    • An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma
    • Agulnik M, et al. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. ASCO Meeting Abstracts. 2009;27(15S):10522.
    • (2009) ASCO Meeting Abstracts , vol.27 , Issue.15 , pp. 10522
    • Agulnik, M.1
  • 107
    • 77956395089 scopus 로고    scopus 로고
    • Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS)
    • • Verschraegen CF, et al. Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS). ASCO Meeting Abstracts. 2008;26(15 suppl):10534. Although a small phase 2 trial, the combination of docetaxel, gemcitabine, and bevacizumab appears very promising.
    • (2008) ASCO Meeting Abstracts , vol.26 , Issue.15 SUPPL. , pp. 10534
    • Verschraegen, C.F.1
  • 108
    • 43549083034 scopus 로고    scopus 로고
    • A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens
    • DOI 10.1634/theoncologist.2008-0065
    • I Ray-Coquard, et al. 2008 A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens Oncologist. 13 4 467 473 18448563 1:CAS:528:DC%2BD1cXmslKksbY%3D A study where the targeted agent is not active despite the presence of molecular target in tumors. Underscores the significance of understanding the underlying biological mechanisms driving tumor progression. (Pubitemid 351679928)
    • (2008) Oncologist , vol.13 , Issue.4 , pp. 467-473
    • Ray-Coquard, I.1    Le Cesne, A.2    Whelan, J.S.3    Schoffski, P.4    Bui, B.N.5    Verweij, J.6    Marreaud, S.7    Van Glabbeke, M.8    Hogendoorn, P.9    Blay, J.-Y.10
  • 109
    • 80051668767 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in patients (pts) with metastatic and/or locally advanced soft tissue and bone sarcomas
    • • Ha HT, et al. Phase II trial of cetuximab in patients (pts) with metastatic and/or locally advanced soft tissue and bone sarcomas. ASCO Meeting Abstracts. 2008;26(15 suppl):10537. A study where the targeted agent is not active despite the presence of molecular target in tumors. Underscores the significance of understanding the underlying biological mechanisms driving tumor progression.
    • (2008) ASCO Meeting Abstracts , vol.26 , Issue.15 SUPPL. , pp. 10537
    • Ha, H.T.1
  • 110
    • 62849105383 scopus 로고    scopus 로고
    • The insulin-like growth factor system and sarcomas
    • 19148905 1:CAS:528:DC%2BD1MXjvFOmu7o%3D
    • B Rikhof, et al. 2009 The insulin-like growth factor system and sarcomas J Pathol. 217 4 469 482 19148905 1:CAS:528:DC%2BD1MXjvFOmu7o%3D
    • (2009) J Pathol. , vol.217 , Issue.4 , pp. 469-482
    • Rikhof, B.1
  • 111
    • 75449117196 scopus 로고    scopus 로고
    • A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas
    • Patel S, et al. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. ASCO Meeting Abstracts. 2009;27(15S):10503.
    • (2009) ASCO Meeting Abstracts , vol.27 , Issue.15 , pp. 10503
    • Patel, S.1
  • 112
    • 80051665996 scopus 로고    scopus 로고
    • A Phase II trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory bone and soft tissue sarcomas excluding ESFT
    • Abstract #900715
    • Pappo A, et al. A Phase II trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory bone and soft tissue sarcomas excluding ESFT. CTOS Meeting Abstracts, 2010(Abstract #900715).
    • (2010) CTOS Meeting Abstracts
    • Pappo, A.1
  • 113
    • 77953641778 scopus 로고    scopus 로고
    • Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: Twenty years from the bench to the bedside
    • 20526094 1:CAS:528:DC%2BC3cXovV2rt74%3D
    • D Olmos, et al. 2010 Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside Cancer J. 16 3 183 194 20526094 1:CAS:528:DC%2BC3cXovV2rt74%3D
    • (2010) Cancer J. , vol.16 , Issue.3 , pp. 183-194
    • Olmos, D.1
  • 114
    • 79251591976 scopus 로고    scopus 로고
    • Updating progress in sarcoma therapy with mTOR inhibitors
    • 20591820
    • JY Blay 2010 Updating progress in sarcoma therapy with mTOR inhibitors Ann Oncol. 22 2 280 287 20591820
    • (2010) Ann Oncol. , vol.22 , Issue.2 , pp. 280-287
    • Blay, J.Y.1
  • 115
    • 78751647387 scopus 로고    scopus 로고
    • Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST
    • Richter S, et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. ASCO Meeting Abstracts. 2010;28(15 suppl):10038.
    • (2010) ASCO Meeting Abstracts , vol.28 , Issue.15 SUPPL. , pp. 10038
    • Richter, S.1
  • 116
    • 37149033966 scopus 로고    scopus 로고
    • Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial
    • • Chawla SP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial. ASCO Meeting Abstracts. 2007;25(18 suppl):10076. An example of a well-designed phase 2 trial that is based on promising evidence from phase 1 and 2 trials, Simon's two-stage design, sound statistical methods (enrolling an adequate number of patients), and segregated patients into cohorts based on their STS histological subtype.
    • (2007) ASCO Meeting Abstracts , vol.25 , Issue.18 SUPPL. , pp. 10076
    • Chawla, S.P.1
  • 117
    • 34447535345 scopus 로고    scopus 로고
    • Engineering targeted viral vectors for gene therapy
    • DOI 10.1038/nrg2141, PII NRG2141
    • R Waehler SJ Russell DT Curiel 2007 Engineering targeted viral vectors for gene therapy Nat Rev Genet. 8 8 573 587 17607305 1:CAS:528: DC%2BD2sXnvVekt78%3D (Pubitemid 47077278)
    • (2007) Nature Reviews Genetics , vol.8 , Issue.8 , pp. 573-587
    • Waehler, R.1    Russell, S.J.2    Curiel, D.T.3
  • 118
    • 69949145988 scopus 로고    scopus 로고
    • Phase I/II and phase II studies of targeted gene delivery in vivo: Intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma
    • 19532136 1:CAS:528:DC%2BD1MXntlGnsLw%3D
    • SP Chawla, et al. 2009 Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma Mol Ther. 17 9 1651 1657 19532136 1:CAS:528:DC%2BD1MXntlGnsLw%3D
    • (2009) Mol Ther. , vol.17 , Issue.9 , pp. 1651-1657
    • Chawla, S.P.1
  • 119
    • 80051663214 scopus 로고    scopus 로고
    • Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous Rexin-G as stand alone therapy for chemotherapy-resistant bone and soft tissue sarcoma
    • Abstract #896893
    • Ganjoo K, et al. Advanced phase I/II evaluation of tumor-targeted gene delivery: intravenous Rexin-G as stand alone therapy for chemotherapy-resistant bone and soft tissue sarcoma. CTOS Meeting Abstracts. 2010(Abstract #896893).
    • (2010) CTOS Meeting Abstracts
    • Ganjoo, K.1
  • 121
    • 43049083694 scopus 로고    scopus 로고
    • Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs
    • 18257544 1:CAS:528:DC%2BD1cXhslWis7s%3D
    • JX Duan, et al. 2008 Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs J Med Chem. 51 8 2412 2420 18257544 1:CAS:528:DC%2BD1cXhslWis7s%3D
    • (2008) J Med Chem. , vol.51 , Issue.8 , pp. 2412-2420
    • Duan, J.X.1
  • 122
    • 79954499054 scopus 로고    scopus 로고
    • Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma
    • Cranmer LD, et al. Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma. ASCO Meeting Abstracts. 2010;28(15 suppl):10036.
    • (2010) ASCO Meeting Abstracts , vol.28 , Issue.15 SUPPL. , pp. 10036
    • Cranmer, L.D.1
  • 124
    • 27144523169 scopus 로고    scopus 로고
    • Gene expression profiling of human sarcomas: Insights into sarcoma biology
    • DOI 10.1158/0008-5472.CAN-05-1699
    • K Baird, et al. 2005 Gene expression profiling of human sarcomas: insights into sarcoma biology Cancer Res. 65 20 9226 9235 16230383 1:CAS:528:DC%2BD2MXhtFWmu7%2FO These references [124-126] highlight the potential of using high-throughput approaches to help understand the underlying biology of STS subtypes (Pubitemid 41507988)
    • (2005) Cancer Research , vol.65 , Issue.20 , pp. 9226-9235
    • Baird, K.1    Davis, S.2    Antonescu, C.R.3    Harper, U.L.4    Walker, R.L.5    Chen, Y.6    Glatfelter, A.A.7    Duray, P.H.8    Meltzer, P.S.9
  • 125
    • 5444251855 scopus 로고    scopus 로고
    • Role of gene expression arrays in sarcomas
    • KM Skubitz AP Skubitz 2004 Role of gene expression arrays in sarcomas Curr Oncol Rep. 6 4 309 314 15161587 These references [124-126] highlight the potential of using high-throughput approaches to help understand the underlying biology of STS subtypes (Pubitemid 39359501)
    • (2004) Current Oncology Reports , vol.6 , Issue.4 , pp. 309-314
    • Skubitz, K.M.1    Skubitz, A.P.N.2
  • 126
    • 33645054041 scopus 로고    scopus 로고
    • The role of microarray technologies in the study of soft tissue tumours
    • 16359534 1:STN:280:DC%2BD2Mnnt1yrug%3D%3D
    • RB West M van de Rijn 2006 The role of microarray technologies in the study of soft tissue tumours Histopathology. 48 1 22 31 16359534 1:STN:280:DC%2BD2Mnnt1yrug%3D%3D These references [124-126] highlight the potential of using high-throughput approaches to help understand the underlying
    • (2006) Histopathology. , vol.48 , Issue.1 , pp. 22-31
    • West, R.B.1    Van De Rijn, M.2
  • 127
    • 23344454965 scopus 로고    scopus 로고
    • Critical issues in response evaluation on computed tomography: Lessons from the gastrointestinal stromal tumor model
    • H Choi 2005 Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model Curr Oncol Rep. 7 4 307 311 15946591 This paper addresses lessons learned from GIST on how response to targeted agents is measured and evaluated (Pubitemid 41149677)
    • (2005) Current Oncology Reports , vol.7 , Issue.4 , pp. 307-311
    • Choi, H.1
  • 128
    • 0035154256 scopus 로고    scopus 로고
    • Clinical trial designs for cytostatic agents: Are new approaches needed?
    • EL Korn, et al. 2001 Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 19 1 265 272 11134222 1:CAS:528: DC%2BD3MXot1Wnsw%3D%3D A critical evaluation of appropriate end points, statistical considerations, and clinical trial designs for testing cytostatic agents (Pubitemid 32063505)
    • (2001) Journal of Clinical Oncology , vol.19 , Issue.1 , pp. 265-272
    • Korn, E.L.1    Arbuck, S.G.2    Pluda, J.M.3    Simon, R.4    Kaplan, R.S.5    Christian, M.C.6
  • 129
    • 0036189675 scopus 로고    scopus 로고
    • Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
    • DOI 10.1016/S0959-8049(01)00398-7, PII S0959804901003987
    • M Van Glabbeke, et al. 2002 Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer. 38 4 543 549 11872347 An important paper characterizing the use of progression-free rate as a primary end point in STS trials (Pubitemid 34185394)
    • (2002) European Journal of Cancer , vol.38 , Issue.4 , pp. 543-549
    • Van Glabbeke, M.1    Verweij, J.2    Judson, I.3    Nielsen, O.S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.